Company Overview and News

 
Harris (HRS) Q1 Earnings and Revenues Surpass Estimates

13h zacks
Harris (HRS - Free Report) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.70 per share. This compares to earnings of $1.38 per share a year ago. These figures are adjusted for non-recurring items.
LGNZZ LGNYZ LGND LGNXZ HRS LGNDZ

5
New Strong Sell Stocks for October 15th

14h zacks
EXFO Inc (EXFO - Free Report) is a developer of smarter network test, monitoring and analytics solutions for communications service providers and network equipment manufacturers. The Zacks Consensus Estimate for its current year earnings has been revised 12.9% downward over the last 60 days.
NINE NYSE ATRO EXFO XOM SPB LGNZZ LGNYZ LGND LGNXZ ATROB LGNDZ

2
This Future Clinical Endpoint Could Make An Instant Blockbuster Out Of Viking's VK5211

20h seekingalpha - 1
Hip fracture is a serious and growing healthcare problem that is in desperate need of focus.
VKTXW LGNZZ LGND LGNYZ LGNXZ VKTX LGNDZ

7
Qualcomm (QCOM) Flat As Market Gains: What You Should Know

2018-10-13 zacks
In the latest trading session, Qualcomm (QCOM - Free Report) closed at $64.29, marking no change from the previous day. This move lagged the S&P 500's daily gain of 1.42%. Meanwhile, the Dow gained 1.15%, and the Nasdaq, a tech-heavy index, added 2.29%.
XOM LGNZZ LGNYZ LGND LGNXZ QCOM LGNDZ

3
Denbury Resources (DNR) Outpaces Stock Market Gains: What You Should Know

2018-10-13 zacks
Denbury Resources (DNR - Free Report) closed the most recent trading day at $5.74, moving +1.95% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.42%. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
DNR XOM LGNZZ LGNYZ LGND LGNXZ LGNDZ

3
Lowe's (LOW) Gains But Lags Market: What You Should Know

2018-10-13 zacks
In the latest trading session, Lowe's (LOW - Free Report) closed at $105.33, marking a +1.06% move from the previous day. The stock lagged the S&P 500's daily gain of 1.42%. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
XOM LGNZZ LGNYZ LGND LGNXZ LGNDZ

3
Comtech Telecommunications (CMTL) Gains But Lags Market: What You Should Know

2018-10-13 zacks
Comtech Telecommunications (CMTL - Free Report) closed at $31.92 in the latest trading session, marking a +0.6% move from the prior day. This move lagged the S&P 500's daily gain of 1.42%. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
CMTL XOM LGNZZ LGNYZ LGND LGNXZ LGNDZ

4
Verso Corporation (VRS) Gains But Lags Market: What You Should Know

2018-10-13 zacks
In the latest trading session, Verso Corporation (VRS - Free Report) closed at $29.56, marking a +0.58% move from the previous day. This change lagged the S&P 500's 1.42% gain on the day. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
VRSZQ VRSZ VRS XOM LGNZZ LGNYZ LGND LGNXZ VRSZW LGNDZ

3
Archer Daniels Midland (ADM) Gains But Lags Market: What You Should Know

2018-10-13 zacks
Archer Daniels Midland (ADM - Free Report) closed at $48.83 in the latest trading session, marking a +0.33% move from the prior day. The stock lagged the S&P 500's daily gain of 1.42%. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
XOM LGNZZ LGNYZ LGND LGNXZ ADM LGNDZ

17
Blackstone Group (BX) Gains But Lags Market: What You Should Know

2018-10-13 zacks
Blackstone Group (BX - Free Report) closed at $34.86 in the latest trading session, marking a +0.77% move from the prior day. This change lagged the S&P 500's 1.42% gain on the day. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
BGX XOM LGNZZ LGNYZ LGND LGNXZ BGLF BX LGNDZ BGB

6
UnitedHealth Group (UNH) Gains But Lags Market: What You Should Know

2018-10-13 zacks
UnitedHealth Group (UNH - Free Report) closed at $259.41 in the latest trading session, marking a +0.89% move from the prior day. This move lagged the S&P 500's daily gain of 1.42%. Elsewhere, the Dow gained 1.15%, while the tech-heavy Nasdaq added 2.29%.
XOM LGNZZ LGNYZ LGND LGNXZ UNH LGNDZ

3
BlackBerry (BB) Gains But Lags Market: What You Should Know

2018-10-13 zacks
BlackBerry (BB - Free Report) closed at $9.60 in the latest trading session, marking a +0.95% move from the prior day. This move lagged the S&P 500's daily gain of 1.42%. Elsewhere, the Dow gained 1.15%, while the tech-heavy Nasdaq added 2.29%.
XOM LGNZZ LGNYZ LGND LGNXZ BB BB LGNDZ

3
Exxon Mobil (XOM) Stock Sinks As Market Gains: What You Should Know

2018-10-13 zacks
In the latest trading session, Exxon Mobil (XOM - Free Report) closed at $81.38, marking a -0.27% move from the previous day. This change lagged the S&P 500's 1.42% gain on the day. Elsewhere, the Dow gained 1.15%, while the tech-heavy Nasdaq added 2.29%.
XOM LGNZZ LGNYZ LGND LGNXZ LGNDZ

6
Berkshire Hathaway Inc. (BRK.B) Gains But Lags Market: What You Should Know

2018-10-13 zacks
In the latest trading session, Berkshire Hathaway Inc. (BRK.B - Free Report) closed at $206.70, marking a +0.74% move from the previous day. This change lagged the S&P 500's 1.42% gain on the day. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
BRK.A XOM LGNZZ LGNYZ LGND LGNXZ LGNDZ

9
Urban Outfitters (URBN) Gains But Lags Market: What You Should Know

2018-10-13 zacks
In the latest trading session, Urban Outfitters (URBN - Free Report) closed at $38.59, marking a +1.37% move from the previous day. This change lagged the S&P 500's 1.42% gain on the day. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
XOM LGNZZ LGNYZ LGND LGNXZ URBN LGNDZ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 53220K181